Clinical Study of Liposomal Paclitaxel in Chinese Patients

NCT ID: NCT00881101

Last Updated: 2009-04-15

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-04-30
• Study Completion Date: 2009-12-31

Brief Summary

The purpose of this study is to determine the maximum tolerated dose and dose limiting toxicities of liposomal paclitaxel in Chinese patients with solid tumors in advanced stages.

Detailed Description

There are clinical trials show that paclitaxel is common option for the treatment of solid tumors. Liposomal paclitaxel has different pharmacokinetic features comparing with conventional paclitaxel. However,the tolerance of this new dosage form of paclitaxel (liposomal paclitaxel) has never been studied in Chinese cancer patients. This study is designed to find the maximum tolerated dose and dose limiting toxicities of liposomal paclitaxel in Chinese cancer patients.

Conditions

Solid Tumor

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

Liposomal paclitaxel

Group Type: EXPERIMENTAL

Liposomal paclitaxel

Intervention Type: DRUG

All Patients will receive liposomal paclitaxel (starting at a dose of 190mg/m2,3h,ivgtt,at d1)each cycle for 1 cycle.

Interventions

Liposomal paclitaxel

All Patients will receive liposomal paclitaxel (starting at a dose of 190mg/m2,3h,ivgtt,at d1)each cycle for 1 cycle.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age: from 18 to 70

2. Patients with solid tuomors at advanced stage must be histologically or cytologically confirmed ,and be suitable for treating with Paclitaxel Liposome solo

3. Eastern Cooperative Oncology Group (ECOG) performance status (PS)is from 0 to 2

4. Patients who are expected to live at least 3 months

5. Laboratory tests before the study: white blood count (WBC)≥4,000/mm³,absolute neutrophil count (ANC) ≥1,500/mm³, platelet count ≥100,000/mm³, hemoglobin≥9.0 g/dL, aspartate aminotransferase AST (sGOT) and alanine aminotransferase ALT(sGPT)≤2.5 times of normal value upper limit，serum creatinine≤1.0 time of normal value upper limit，total bilirubin≤1.5 times of normal value upper limit

6. Not using chemotherapeutics (including test drug)before the study trial at least 4 weeks

7. No obvious functional disturbance diseases of internal organs

8. Complying with the study protocol

9. Sign informed consent

10. No Previous anaphylactic reaction to hormone

Exclusion Criteria

1. Allergy to any medication or foods; History of hypersensitivity reactions to the conventional dosage form of paclitaxel or correlate excipients

2. Active uncontrolled central nervous system metastasis

3. Severe complications that obviously influence the compliance of patients

4. Grade ≥1 neuropathy using NCI CTCAE version 3.0 criteria

5. Taking other study medications or participating other clinical trial within 4w

6. Having radiation therapy or operation within 4w

7. Any non-remission toxicity ≥ CTC 1 in prior anticancer therapy(including radiation therapy) (except alopecie and hemoglobin)

8. Pregnant or lactant women; fertile patients not using effective contraception during study

9. No chief organ functional disturbance or diseases:

• abnormal liver and renal functions
• myocardial infarction
• active heart disease
• neuropathy or mental diseases including dementia or epilepsy
• blind、deaf、dumb or extremity disability
• known infection
• active diffuse intravascular coagulation

10. Others whom researchers regard not eligible for the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Nanjing Sike Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Cancer Hospital of Fudan University

Principal Investigators

Jin Li, Dr.

Role: PRINCIPAL_INVESTIGATOR

Cancer Hospital of Fudan University

Locations

The ethics committee of Cancer Hospital of Fudan University

Shanghai, Shanghai Municipality, China

Countries

China

Other Identifiers

LPS- PH I -01-2009

Identifier Type: -

Identifier Source: org_study_id